Medical Devices

Request for TOC Request for Sample
BUY NOW

Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market – Industry Trends and Forecast to 2029

Medical Devices | Published Report | Dec 2021 | Europe | 350 Pages | No of Tables: 54 | No of Figures: 34

Report Description

Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market, By Technology (CTC Detection Methods, CTC Enrichment Methods, Ex Vivo Positive Selection, Molecular (RNA)-Based Technologies, Functional In vitro Cell Invasion Assay, Xenotransplantation Models, Microchips, Single Spiral Microchannel, Negative Selection & Immunocytochemical Technologies), Application (Cancer Stem Cell Research, Multiple Chromosome Abnormalities & Others), End User (Research & Academic Institutes, Reference Laboratories & Hospitals & Physician Laboratories),Country (Germany, France, U.K., Hungary, Lithuania, Austria, Ireland, Norway, Poland, Italy, Spain, Russia, Turkey, Netherlands, Switzerland’s, Rest of Europe) - Industry Trends and Forecast -2029

Get Exclusive Sample Copy of this Report Here

Market Analysis and Insights: Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market

Europe circulating tumor cells (CTC) liquid biopsy market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 24.3% in the forecast period of 2022 to 2029 and is expected to reach USD 1,891.60 million by 2029 from USD 351.05 million in 2021. The high prevalence of chronic diseases and increasing R&D activities for its effective application is likely to be the major drivers which propel the demand of the market in the forecast period.

The liquid biopsy is a non-invasive blood test which detects circulating tumor cells and tumor DNA fragments which are released into the blood from primary tumors and metastatic sites. It is a simple and precise alternative to surgical biopsy procedure, which allows surgeon to detect cancer at a very early stage.

The circulating tumor cells are a rare sub-set of cells which function as a seed of metastases. It is found in blood of patients who have developed solid tumors. The testing of circulating tumor cells allows the detection and quantification of tumor cells in the blood of cancer patients. The various types of biological phenotypes of circulating tumor cells (CTCs) exits includes stem cell-like or mixed, mesenchymal or epithelial. These phenotypes are present in blood in a very small quantity. Due to which, their detection needs a phase of isolation-enrichment. After that, a second phase of detection.

The growing demand of circulating tumor cells (CTC) liquid biopsy because of their efficacy, high prevalence of cancer are the major drivers propelling the demand for circulating tumor cells (CTC) liquid biopsy market in the forecast period. However, the unclear regulatory and reimbursement scenario, shortage of skilled personnel is restraining the circulating tumor cells (CTC) liquid biopsy market growth in the forecast period. 

Europe circulating tumor cells (CTC) liquid biopsy market report provides details of market share, new developments, and impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an Analyst Brief. Our team will help you create a revenue impact solution to achieve your desired goal.


Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market Scope and Market Size

Europe circulating tumor cells (CTC) liquid biopsy market is categorized into three notable segments which are based on technology, application and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of technology, circulating tumor cells (CTC) liquid biopsy market is segmented into CTC detection methods, CTC enrichment methods, ex vivo positive selection, molecular (RNA)-based technologies, functional in vitro cell invasion assay, xenotransplantation methods, microchips, single spiral microchannel, negative selection and immunocytochemical technologies  In 2021, CTC detection methods segment is expected to dominate the market because of increasing use of this technology in the academics and research centers for the tests of liquid biopsy.
  • On the basis of application, circulating tumor cells (CTC) liquid biopsy market is segmented into cancer stem cell research, multiple chromosome abnormalities and others. In 2021, cancer stem cell research segment is expected to dominate the market because of increasing demand of early diagnosis and treatment of cancer.
  • On the basis of end user, circulating tumor cells (CTC) liquid biopsy market is segmented into research and academic institutes, reference laboratories and hospitals and physician laboratories. In 2021, academic and research institutes segment is expected to dominate the market because of research and academic institutes perform an essential role to accelerate research and development in the various therapeutic area related to liquid biopsies.

Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market Country Level Analysis

Europe circulating tumor cells (CTC) liquid biopsy market is analysed and market size information is provided by country, technology, application and end user.

The countries covered in the Europe circulating tumor cells (CTC) liquid biopsy market report are Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Rest of Europe

Germany is dominating the circulating tumor cells (CTC) liquid biopsy market in the European region due to presence of untapped opportunities in Germany and growing geriatric population in Germany.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data. 

The Presence of Advanced Technology and Strategic Initiatives Taken by Players are Creating New Opportunities in The Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market 

Europe circulating tumor cells (CTC) liquid biopsy market also provides you with detailed market analysis for every country's growth in a particular industry with products sales, the impact of advancement in the market, and changes in regulatory scenarios with their support for the circulating tumor cells (CTC) liquid biopsy market. The data is available for the historic period 2011 to 2019.

Competitive Landscape and Europe Circulating Tumor Cells (CTC) Liquid Biopsy Market Share Analysis

Europe circulating tumor cells (CTC) liquid biopsy market competitive landscape provide details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company's focus related to circulating tumor cells (CTC) liquid biopsy market.

The major companies which are dealing in the circulating tumor cells (CTC) liquid biopsy market are Eurofins Genomics ( a subsidiary of Eurofins Scientific), MDx Health, Guardant Health, IMMUCOR, Thermo Fisher Scientific, Inc., Menarini Silicon Biosystems, QIAGEN, Exact Sciences Corporation, Myriad Genetics, Inc., LungLife AI, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc. , Natera Inc.,  ExoDx ( a subsidiary of Bio-Techne Corporation), Biocept, Inc., F. Hoffman-La Roche Ltd. ,FOUNDATION MEDICINE, INC., Lucence Health, Inc., Inivata Ltd, Biolidics Limited, Vortex Biosciences among others.

For instance,

  • In November 2021, Myriad Genetics, Inc. announced that it had received accreditation from College of American Pathologists. This will increase the market position of the company.

Collaboration, joint ventures, and other strategies by the market player is enhancing the company market in the circulating tumor cells (CTC) liquid biopsy market, which also provides the benefit for the organization to improve their offering for circulating tumor cells (CTC) liquid biopsy market.

 

 


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TECHNOLOGY LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTERS FIVE FORCES

5 REGULATIONS: EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET

5.1 ROLE OF FDA

5.2 ROLE OF CDC AND HCFA

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 HIGH PREVALENCE OF CANCER

6.1.2 ADVANTAGES OF LIQUID BIOPSY OVER SURGICAL BIOPSY

6.1.3 GOVERNMENT INITIATIVES TO SPREAD AWARENESS ABOUT EARLY DIAGNOSIS OF CANCER

6.1.4 RISE IN FDA APPROVAL

6.1.5 HEALTHCARE REIMBURSEMENT FOR LIQUID BIOPSY

6.2 RESTRAINTS

6.2.1 DOWNSIDES OF LIQUID BIOPSY

6.2.2 RAPID DEVELOPMENT OF ULTRASENSITIVE IMAGING TECHNOLOGIES SUCH AS MAGNETIC RESONANCE IMAGING

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS

6.3.2 RISE IN HEALTHCARE EXPENDITURE AND DISPOSABLE INCOME

6.3.3 INCREASE IN RESEARCH AND DEVELOPMENT ACTIVITIES

6.3.4 HUGE MARKET POTENTIAL IN DEVELOPING COUNTRIES

6.4 CHALLENGES

6.4.1 SHORTAGE OF SKILLED PERSONNEL

6.4.2 LACK OF ACCESSIBILITY

7 COVID-19 IMPACT ON EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET

7.1 IMPACT ON PRICE

7.2 IMPACT ON DEMAND

7.3 IMPACT ON SUPPLY

7.4 KEY INITIATIVES BY MARKET PLAYER DURING COVID 19

7.5 CONCLUSION:

8 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY

8.1 OVERVIEW

8.2 CTC DETECTION METHODS

8.3 CTC ENRICHMENT METHODS

8.4 EX VIVO POSITIVE SELECTION

8.5 MOLECULAR (RNA)-BASED TECHNOLOGIES

8.6 FUNCTIONAL IN VITRO CELL INVASION ASSAY

8.7 XENOTRANSPLANTATION MODELS

8.8 MICROCHIPS

8.9 SINGLE SPIRAL MICROCHANNEL

8.1 NEGATIVE SELECTION

8.11 IMMUNOCYTOCHEMICAL TECHNOLOGIES

9 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION

9.1 OVERVIEW

9.2 CANCER STEM CELL RESEARCH

9.3 MULTIPLE CHROMOSOME ABNORMALITIES

9.4 OTHERS

10 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER

10.1 OVERVIEW

10.2 RESEARCH & ACADEMIC INSTITUTES

10.3 REFERENCE LABORATORIES

10.4 HOSPITALS AND PHYSICIAN LABORATORIES

11 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION

11.1 EUROPE

11.1.1 GERMANY

11.1.2 FRANCE

11.1.3 U.K.

11.1.4 ITALY

11.1.5 RUSSIA

11.1.6 SPAIN

11.1.7 TURKEY

11.1.8 NETHERLANDS

11.1.9 SWITZERLAND

11.1.10 BELGIUM

11.1.11 REST OF EUROPE

12 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: EUROPE

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 GUARDANT HEALTH

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENTS

14.2 EUROFINS GENOMICS (A SUBSIDIARY OF EUROFINS SCIENTIFIC)

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 FOUNDATION MEDICINE, INC.

14.3.1 COMPANY SNAPSHOT

14.3.2 COMPANY SHARE ANALYSIS

14.3.3 PRODUCT PORTFOLIO

14.3.4 RECENT DEVELOPMENTS

14.4 ILLUMINA, INC.

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENT

14.5 NATERA, INC.

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENT

14.6 BIO-RAD LABORATORIES, INC.

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENT

14.7 QIAGEN

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENTS

14.8 THERMO FISHER SCIENTIFIC INC.

14.8.1 COMPANY SNAPSHOT

14.8.2 REVENUE ANALYSIS

14.8.3 PRODUCT PORTFOLIO

14.8.4 RECENT DEVELOPMENTS

14.9 BIOCEPT, INC.

14.9.1 COMPANY SNAPSHOT

14.9.2 REVENUE ANALYSIS

14.9.3 PRODUCT PORTFOLIO

14.9.4 RECENT DEVELOPMENT

14.1 BIOLIDICS LIMITED

14.10.1 COMPANY SNAPSHOT

14.10.2 REVENUE ANALYSIS

14.10.3 PRODUCT PORTFOLIO

14.10.4 RECENT DEVELOPMENTS

14.11 EXACT SCIENCES CORPORATION

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENT

14.12 EXODX (A SUBSIDIARY OF BIO-TECHNE CORPORATION)

14.12.1 COMPANY SNAPSHOT

14.12.2 REVENUE ANALYSIS

14.12.3 PRODUCT PORTFOLIO

14.12.4 RECENT DEVELOPMENTS

14.13 F. HOFFMANN-LA ROCHE LTD

14.13.1 COMPANY SNAPSHOT

14.13.2 RECENT FINANCIALS

14.13.3 PRODUCT PORTFOLIO

14.13.4 RECENT DEVELOPMENTS

14.14 IMMUCOR

14.14.1 COMPANY SNAPSHOT

14.14.2 PRODUCT PORTFOLIO

14.14.3 RECENT DEVELOPMENTS

14.15 INIVATA LTD

14.15.1 COMPANY SNAPSHOT

14.15.2 PRODUCT PORTFOLIO

14.15.3 RECENT DEVELOPMENTS

14.16 LUCENCE HEALTH, INC.

14.16.1 COMPANY SNAPSHOT

14.16.2 PRODUCT PORTFOLIO

14.16.3 RECENT DEVELOPMENTS

14.17 LUNGLIFE AI, INC.

14.17.1 COMPANY SNAPSHOT

14.17.2 PRODUCT PORTFOLIO

14.17.3 RECENT DEVELOPMENTS

14.18 MDXHEALTH

14.18.1 COMPANY SNAPSHOT

14.18.2 REVENUE ANALYSIS

14.18.3 PRODUCT PORTFOLIO

14.18.4 RECENT DEVELOPMENT

14.19 MENARINI SILICON BIOSYSTEMS

14.19.1 COMPANY SNAPSHOT

14.19.2 PRODUCT PORTFOLIO

14.19.3 RECENT DEVELOPMENTS

14.2 MYRIAD GENETICS, INC.

14.20.1 COMPANY SNAPSHOT

14.20.2 REVENUE ANALYSIS

14.20.3 PRODUCT PORTFOLIO

14.20.4 RECENT DEVELOPMENTS

14.21 VORTEX BIOSCIENCES

14.21.1 COMPANY SNAPSHOT

14.21.2 PRODUCT PORTFOLIO

14.21.3 RECENT DEVELOPMENTS

15 QUESTIONNAIRE

16 RELATED REPORTS

List of Table

TABLE 1 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 2 EUROPE CTC DETECTION METHODS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 EUROPE CTC ENRICHMENT METHODS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 EUROPE EX VIVO POSITIVE SELECTION IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 EUROPE MOLECULAR (RNA)-BASED TECHNOLOGIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 EUROPE FUNCTIONAL IN VITRO CELL INVASION ASSAY IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 EUROPE XENOTRANSPLANTATION MODELS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 EUROPE MICROCHIPS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 EUROPE SINGLE SPIRAL MICROCHANNEL IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 EUROPE NEGATIVE SELECTION IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 EUROPE IMMUNOCYTOCHEMICAL TECHNOLOGIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 13 EUROPE CANCER STEM CELL RESEARCH IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 EUROPE MULTIPLE CHROMOSOME ABNORMALITIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 EUROPE OTHERS IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 17 EUROPE RESEARCH & ACADEMIC INSTITUTES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 EUROPE REFERENCE LABORATORIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 EUROPE HOSPITALS AND PHYSICIAN LABORATORIES IN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 21 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 22 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 23 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 24 GERMANY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 25 GERMANY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 26 GERMANY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 27 FRANCE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 28 FRANCE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 29 FRANCE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 30 U.K. CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 31 U.K. CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 32 U.K. CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 33 ITALY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 34 ITALY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 35 ITALY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 36 RUSSIA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 37 RUSSIA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 38 RUSSIA CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 39 SPAIN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 40 SPAIN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 41 SPAIN CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 42 TURKEY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 43 TURKEY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 44 TURKEY CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 45 NETHERLANDS CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 46 NETHERLANDS CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 47 NETHERLANDS CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 48 SWITZERLAND CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 49 SWITZERLAND CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 50 SWITZERLAND CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 51 BELGIUM CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 52 BELGIUM CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2029 (USD MILLION)

TABLE 53 BELGIUM CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 54 REST OF EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: SEGMENTATION

FIGURE 2 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: DROC ANALYSIS

FIGURE 4 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET : EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET : COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: SEGMENTATION

FIGURE 11 THE HIGH PREVALENCE OF CANCER IS EXPECTED TO DRIVE THE EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 CTC DETECTION METHODS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET IN 2022 & 2029

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET

FIGURE 15 PREVALENCE OF BREAST CANCER IN EUROPE, INDIA, AND IN THE U.S.

FIGURE 16 PREVALENCE OF LUNG CANCER IN VARIOUS COUNTRIES, WITH HUNGARY BEING THE HIGHEST PREVALENCE RATE IN WOMEN AND MEN

FIGURE 17 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2021

FIGURE 18 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2020-2029 (USD MILLION)

FIGURE 19 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, CAGR (2022-2029)

FIGURE 20 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, LIFELINE CURVE

FIGURE 21 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, 2021

FIGURE 22 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, 2020-2029 (USD MILLION)

FIGURE 23 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 24 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 25 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, 2021

FIGURE 26 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 27 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, CAGR (2022-2029)

FIGURE 28 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, LIFELINE CURVE

FIGURE 29 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: SNAPSHOT (2021)

FIGURE 30 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY COUNTRY (2021)

FIGURE 31 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY COUNTRY (2022 & 2029)

FIGURE 32 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY COUNTRY (2021 & 2029)

FIGURE 33 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY (2022-2029)

FIGURE 34 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: COMPANY SHARE 2021 (%)

View Infographics

FIGURE 1 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: SEGMENTATION

FIGURE 2 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: DROC ANALYSIS

FIGURE 4 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET : EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET : COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: DBMR MARKET POSITION GRID

FIGURE 8 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: SEGMENTATION

FIGURE 11 THE HIGH PREVALENCE OF CANCER IS EXPECTED TO DRIVE THE EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 CTC DETECTION METHODS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET IN 2022 & 2029

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET

FIGURE 15 PREVALENCE OF BREAST CANCER IN EUROPE, INDIA, AND IN THE U.S.

FIGURE 16 PREVALENCE OF LUNG CANCER IN VARIOUS COUNTRIES, WITH HUNGARY BEING THE HIGHEST PREVALENCE RATE IN WOMEN AND MEN

FIGURE 17 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2021

FIGURE 18 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2020-2029 (USD MILLION)

FIGURE 19 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, CAGR (2022-2029)

FIGURE 20 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY, LIFELINE CURVE

FIGURE 21 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, 2021

FIGURE 22 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, 2020-2029 (USD MILLION)

FIGURE 23 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, CAGR (2022-2029)

FIGURE 24 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 25 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, 2021

FIGURE 26 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, 2020-2029 (USD MILLION)

FIGURE 27 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, CAGR (2022-2029)

FIGURE 28 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY END USER, LIFELINE CURVE

FIGURE 29 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: SNAPSHOT (2021)

FIGURE 30 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY COUNTRY (2021)

FIGURE 31 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY COUNTRY (2022 & 2029)

FIGURE 32 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY COUNTRY (2021 & 2029)

FIGURE 33 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: BY TECHNOLOGY (2022-2029)

FIGURE 34 EUROPE CIRCULATING TUMOR CELLS (CTC) LIQUID BIOPSY MARKET: COMPANY SHARE 2021 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 8500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19